Enroll-HD
is a worldwide observational study of HD families, and monitors people, both with and without the expanded HD gene, on a yearly basis. Enroll-HD Ä¢¹½tvÊÓƵ combines the talents of our Genetics Researchers, Neurologists and local HDA to provide a multi-disciplinary approach to HD research and management.
HD Clarity
has been running in Ä¢¹½tvÊÓƵ since the middle of 2017. The study aims to collect and store high quality samples of CSF (the fluid found in the brain and spinal cord) from people at various stages of HD, as well as healthy controls. The study then makes these samples available for researchers around the globe.
Generation HD2 – Roche
A clinical trial of Tominersen which compares 100mg v placebo in participants with prodromal and early manifest Huntington’s Disease. The clinical trial treatment is given as an injection by lumbar puncture. The main trial endpoints are the safety and efficacy of the CTIMP with efficacy measured by changes in motor function, cognition and performance in the activities of daily living.
The trial is currently in follow-up but closed to recruitment.